UK's GSK to buy US-based cancer drugmaker Nuvalent for $10.6 billion
British drugmaker GSK on Tuesday agreed to acquire U.S.-listed cancer drug developer Nuvalent for $10.6 billion to boost its lung cancer portfolio.
The all-cash deal values Nuvalent at approximately $124 per share, a 40% premium to its last closing price.
(Reporting by DhanushVignesh Babu and Yadarisa Shabong in Bengaluru; Editing by Mrigank Dhaniwala)
Copyright Reuters or USA Today Network via Reuters Connect
This story was originally published June 9, 2026 at 2:07 AM.